Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postbiotic + Anti-PD-1 in Advanced Melanoma
NCT07050940Recruiting
- Sponsor
- Azienda Ospedaliera di Perugia
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Azienda Ospedaliera di Perugia. Primary endpoint: Biological Response Rate at 18 months. Started Feb 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07050940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050940.